BRAF and melanoma: Vemurafenib, a selective BRAF inhibitor, has been approved by FDA for the treatment of patients with metastatic BRAFV600E-mutated melanoma, as it owns dose-dependent anti-proliferative and apoptotic effects in melanoma cells [74].